Ra Medical Systems Inc. (RMED) shares gained 10.71% in the after-market on Wednesday, April 28, 2021, after losing 3.97% in the morning session to close at $4.11. RMED shares have sink 84.04% over the last 12 months, and they have moved up by 10.19% in the past week. Over the past three months, the stock has lost 41.29%, while over the past six months, it has shed 29.44%.
Let’s try to find out is there any reason behind its flipping on Wednesday?
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Enrollment Update about the clinical trial of DABRA
On April 20, 2021, RA Medical Systems Inc reported an increase in enrollment in its pivotal clinical trial to assess the safety and effectiveness of the DABRA excimer laser system. As of April 19, 2021, a total of 42 patients have been enrolled.
The DABRA excimer laser system received U.S. FDA 510(k) clearance in May 2017 for crossing chronic total occlusions.
Upcoming financial results announcement
On April 19, 2021, RA Medical Systems Inc said that it will release its first-quarter 2021 financial results after market close on Tuesday, May 11, 2021.
A conference call has been organized on the same day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.
Q4 and FY-2020 financial results
The company filed its audited financial statements for the fiscal year ended December 31, 2020, on Form 10-Kwith the Securities and Exchange Commission on March 17, 2021.
Q4 2020 financial highlights
- Q4 2020 net revenue was $1.2 million, compared with net revenue of $1.4 million for the fourth quarter of 2019.
- Selling, general and administrative expenses were $6.9 million in Q4 2020 compared with $8.6 million for the fourth quarter of 2019.
- Research and development expenses for the fourth quarter of 2020 were $3.4 million compared with $0.8 million for the fourth quarter of 2019.
- RA Medical Systems suffered a net loss of 4 million, or $3.61 per share in Q4 2020 compared to a net loss of $9.7 million, or $18.04 per share in Q4 2019.
- Adjusted EBITDA was -$8.8 million for the reported quarter, compared with negative $8.0 million for the fourth quarter of 2019.
- As of December 31, 2020, Ra Medical had cash and cash equivalents of $23.9 million.
FY2020 financial highlights
- FY 2020 net revenue was $4.4 million compared with net revenue of $7.2 million for 2019.
- Selling, general and administrative expenses were $26.0 million in FY 2020 compared with $51.5 million for 2019.
- Research and development expenses for 2020 were $9.0 million compared with $4.5 million for 2019.
- RA Medical Systems had a net loss of 0 million or $21.22 per share in FY 2020 compares with a net loss of $57.0 million, or $108.28 per share in 2019.
- Adjusted EBITDA was negative $29.6 million in 2020 compared with negative $32.4 million for 2019.
There is no recent news except an update about the DABRA patient enrollment on April 20 which we do not think so is the reason behind its turnaround on Wednesday. Also, it’s hard to predict its future performance at this moment.